Saltar al contenido
Merck

1292303

USP

Glimepiride

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

Glimepiride

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

En este momento no podemos mostrarle ni los precios ni la disponibilidad

Acerca de este artículo

Fórmula empírica (notación de Hill):
C24H34N4O5S
Número CAS:
Peso molecular:
490.62
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

Saltar a

Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

Glimepiride, United States Pharmacopeia (USP) Reference Standard

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

grade

pharmaceutical primary standard

API family

glimepiride

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

¿Está buscando productos similares? Visita Guía de comparación de productos

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
Y0000515BP1144Y0000516
Glimepiride European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepiride

Glimepiride British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepiride

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

API family

glimepiride

API family

glimepiride

API family

glimepiride

API family

glimepiride

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Glimepiride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Glimepiride Tablets
  • Pioglitazone and Glimepiride Tablets

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Potent blocker of cardiac KATP channels.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Repr. 2

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

J Rosenstock et al.
Diabetes care, 19(11), 1194-1199 (1996-11-01)
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. Of the previously treated NIDDM patients, 416 entered this multicenter
T F Veneman et al.
The Netherlands journal of medicine, 52(5), 179-186 (1998-07-04)
Disturbances in insulin secretion and insulin action are both involved in the pathophysiology of type 2 (or non-insulin-dependent) diabetes mellitus. The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and
Mary T Korytkowski
Pharmacotherapy, 24(5), 606-620 (2004-05-28)
Sulfonylureas, which have evolved through two generations since their introduction nearly 50 years ago, remain the most frequently prescribed oral agents for treatment of patients with type 2 diabetes mellitus. Glyburide, glipizide, and glimepiride, the newest sulfonylureas, are as effective
H D Langtry et al.
Drugs, 55(4), 563-584 (1998-04-30)
Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non-insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and
M Nauck et al.
Diabetes, obesity & metabolism, 15(3), 204-212 (2012-09-19)
To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. In the 26-week the Liraglutide Effect and Action in Diabetes

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico